Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z)

Norio Komatsu; Keita Kirito; Kazuya Shimoda; Takayuki Ishikawa; Kohshi Ohishi; Kazuma Ohyashiki; Naoto Takahashi; Hikaru Okada; Taro Amagasaki; Toshio Yonezu; Koichi Akashi

doi:10.1007/s12185-017-2196-2

Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z)

Norio Komatsu, Keita Kirito, Kazuya Shimoda, Takayuki Ishikawa, Kohshi Ohishi, Kazuma Ohyashiki, Naoto Takahashi, Hikaru Okada, Taro Amagasaki, Toshio Yonezu, Koichi Akashi

Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The author would like to correct the error in the publication of the original article. The corrected detail is given below for your reading: The first sentence in the “Results” section under the heading“Patients” should read as“A total of 51 patients were enrolled in this study from April 2014 to September 2014.”

Original language	English
Pages (from-to)	387
Number of pages	1
Journal	International journal of hematology
Volume	105
Issue number	3
DOIs	https://doi.org/10.1007/s12185-017-2196-2
Publication status	Published - Mar 1 2017

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.1007/s12185-017-2196-2

Fingerprint

Dive into the research topics of 'Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z)'. Together they form a unique fingerprint.

Cite this

Komatsu, N., Kirito, K., Shimoda, K., Ishikawa, T., Ohishi, K., Ohyashiki, K., Takahashi, N., Okada, H., Amagasaki, T., Yonezu, T., & Akashi, K. (2017). Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z). International journal of hematology, 105(3), 387. https://doi.org/10.1007/s12185-017-2196-2

Erratum to : Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z). / Komatsu, Norio; Kirito, Keita; Shimoda, Kazuya et al.

In: International journal of hematology, Vol. 105, No. 3, 01.03.2017, p. 387.

Research output: Contribution to journal › Comment/debate › peer-review

Komatsu, N, Kirito, K, Shimoda, K, Ishikawa, T, Ohishi, K, Ohyashiki, K, Takahashi, N, Okada, H, Amagasaki, T, Yonezu, T & Akashi, K 2017, 'Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z)', International journal of hematology, vol. 105, no. 3, pp. 387. https://doi.org/10.1007/s12185-017-2196-2

Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K et al. Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z). International journal of hematology. 2017 Mar 1;105(3):387. https://doi.org/10.1007/s12185-017-2196-2

@article{79890e875f6747a9b230ce7cf34b9ccd,

title = "Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z)",

abstract = "The author would like to correct the error in the publication of the original article. The corrected detail is given below for your reading: The first sentence in the “Results” section under the heading“Patients” should read as“A total of 51 patients were enrolled in this study from April 2014 to September 2014.”",

author = "Norio Komatsu and Keita Kirito and Kazuya Shimoda and Takayuki Ishikawa and Kohshi Ohishi and Kazuma Ohyashiki and Naoto Takahashi and Hikaru Okada and Taro Amagasaki and Toshio Yonezu and Koichi Akashi",

year = "2017",

month = mar,

day = "1",

doi = "10.1007/s12185-017-2196-2",

language = "English",

volume = "105",

pages = "387",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "3",

}

TY - JOUR

T1 - Erratum to

T2 - Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z)

AU - Komatsu, Norio

AU - Kirito, Keita

AU - Shimoda, Kazuya

AU - Ishikawa, Takayuki

AU - Ohishi, Kohshi

AU - Ohyashiki, Kazuma

AU - Takahashi, Naoto

AU - Okada, Hikaru

AU - Amagasaki, Taro

AU - Yonezu, Toshio

AU - Akashi, Koichi

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The author would like to correct the error in the publication of the original article. The corrected detail is given below for your reading: The first sentence in the “Results” section under the heading“Patients” should read as“A total of 51 patients were enrolled in this study from April 2014 to September 2014.”

AB - The author would like to correct the error in the publication of the original article. The corrected detail is given below for your reading: The first sentence in the “Results” section under the heading“Patients” should read as“A total of 51 patients were enrolled in this study from April 2014 to September 2014.”

UR - http://www.scopus.com/inward/record.url?scp=85011827244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011827244&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2196-2

DO - 10.1007/s12185-017-2196-2

M3 - Comment/debate

C2 - 28176224

AN - SCOPUS:85011827244

VL - 105

SP - 387

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -

Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this